...data for DMD candidate Catena idebenone. The poorest performers in the sub-$200 million group included QRxPharma Ltd....
...lost 90% and 87%, respectively. In April, an FDA panel unanimously voted against approval of QRxPharma's...
...Station, N.J. National Institutes of Health (NIH), Bethesda, Md. Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn. QRxPharma Ltd....

...FDA issued a complete response letter to QRxPharma for MoxDuo IR morphine/oxycodone to treat moderate to...
...Paladin Labs Inc. (see BioCentury, Dec. 9, 2013). Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland QRxPharma Ltd....

...containing 10% rose bengal disodium, has completed a Phase II trial to treat recurrent melanoma. QRxPharma Ltd....
...over oxycodone and morphine alone, either by efficacy, or safety, in an appropriate patient population." QRxPharma...

...FDA issued a complete response letter to QRxPharma Ltd. (ASX:QRX; OTCQX:QRXPY) for MoxDuo IR morphine/oxycodone to treat...
...did not provide evidence that it was safer than its individual components at comparable doses. QRxPharma...

...FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 14-0 against approval of QRxPharma's MoxDuo IR...
...Paladin Labs Inc. (see BioCentury, Dec. 9, 2013). Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland QRxPharma Ltd....

...to treat HCV genotype 1 infection. Enanta helped discover ABT-450, an HCV NS3/4A protease inhibitor. QRxPharma Ltd....
...IR is safer than its individual components. The product has a May 25 PDUFA date. QRxPharma...

...and Analgesic Drug Products Advisory Committee voted 14-0 against approval of MoxDuo IR morphine/oxycodone from QRxPharma Ltd....
...morphine, has a May 25 PDUFA date (see BioCentury Extra, April 18) . Trading of QRxPharma...

...been "unable to conclude that there is a safety benefit" for MoxDuo IR morphine/oxycodone from QRxPharma Ltd....